Vol 25, No 4 (2018)
Original articles — Interventional cardiology
Published online: 2017-12-01

open access

Page views 1381
Article views/downloads 1221
Get Citation

Connect on Social Media

Connect on Social Media

Long-term outcomes after percutaneous revascularization of complex coronary bifurcation lesions using a dedicated self-expanding biolimus-eluting stent system

Andreas S. Triantafyllis1, Johan Bennett1, Efstathios Pagourelias1, Keir McCutcheon1, Tom Adriaenssens12, Peter R. Sinnaeve12, Walter Desmet12, Christophe Dubois12
Pubmed: 29240962
Cardiol J 2018;25(4):470-478.


Background: To evaluate long-term clinical outcomes after treatment of complex bifurcation lesions with the AXXESS dedicated self-expanding biolimus A9-eluting bifurcation stent.
Methods: Between 2004 and 2013, 123 patients with complex bifurcation lesions were treated in a single-center with the AXXESS stent in the proximal main vessel (MV) and additional drug-eluting stents in branches when required. Median follow-up was 5 years. Primary endpoint was the rate of major adverse cardiac events (MACE). Secondary endpoints included MACE components (cardiac death, non-periprocedural clinical myocardial infarction [MI], target lesion revascularization [TLR] and definite/probable stent thrombosis [ST]) as well as all-cause death, target vessel revascularization (TVR) and non-TVR.
Results: During follow-up, 11 (8.9%) patients experienced a MACE, of whom 2 (1.6%) suffered cardiac death, 2 (1.6%) had a non-periprocedural clinical MI requiring TLR, and 7 (5.7%) underwent elective TLR. No definite/probable ST was observed. All-cause death occurred in 9 (7.3%) patients, TVR in 11 (8.9%) and non-TVR in 11 (8.9%). Patients treated for left main (LM) bifurcation lesions were more likely to experience MACE than non-LM bifurcation lesions (25% vs. 6.5%, p = 0.04).
Conclusions: Percutaneous revascularization of complex bifurcation lesions with the AXXESS stent is safe and provides excellent long-term results, especially in non-LM lesions.

Article available in PDF format

View PDF Download PDF file


  1. Stankovic G, Lassen JF, Hildick-Smith D, et al. The EuroIntervention coronary bifurcation treatment supplement. EuroIntervention. 2015; 11 Suppl V: V9–11.
  2. Behan MW, Holm NR, Curzen NP, et al. Simple or complex stenting for bifurcation coronary lesions: a patient-level pooled-analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. Circ Cardiovasc Interv. 2011; 4(1): 57–64.
  3. Dubois C, Bennett J, Dens J, et al. COmplex coronary Bifurcation lesions: RAndomized comparison of a strategy using a dedicated self-expanding biolimus-eluting stent versus a culotte strategy using everolimus-eluting stents: primary results of the COBRA trial. EuroIntervention. 2016; 11(13): 1457–1467.
  4. Iakovou I, Ge L, Colombo A. Contemporary stent treatment of coronary bifurcations. J Am Coll Cardiol. 2005; 46(8): 1446–1455.
  5. Farb A, Burke AP, Kolodgie FD, et al. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation. 2003; 108(14): 1701–1706.
  6. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007; 115(18): 2435–2441.
  7. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293(17): 2126–2130.
  8. Lefèvre T, Chevalier B, Louvard Y. Is there a need for dedicated bifurcation devices? EuroIntervention. 2010; 6 Suppl J: J123–J129.
  9. Buysschaert I, Dubois CL, Dens J, et al. Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study. EuroIntervention. 2013; 9(5): 573–581.
  10. Hasegawa T, Ako J, Koo BK, et al. Analysis of left main coronary artery bifurcation lesions treated with biolimus-eluting DEVAX AXXESS plus nitinol self-expanding stent: intravascular ultrasound results of the AXXENT trial. Catheter Cardiovasc Interv. 2009; 73(1): 34–41.
  11. Miyazawa A, Ako J, Hassan A, et al. Analysis of bifurcation lesions treated with novel drug-eluting dedicated bifurcation stent system: intravascular ultrasound results of the AXXESS PLUS trial. Catheter Cardiovasc Interv. 2007; 70(7): 952–957.
  12. Dubois CL, Wijns W. The AXXESS™ self-expanding biolimus A9™ eluting stent system for coronary bifurcation lesions. EuroIntervention. 2010; 6 Suppl J: J130–J134.
  13. Cutlip DE, Windecker S, Mehran R, et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115(17): 2344–2351.
  14. Medina A, Lezo JS, Pan M. A new classification of coronary bifurcation lesions. Rev Esp Cardiol. 2006; 59(2): 183.
  15. Bennett J, Dubois C. Coronary bifurcation lesions: is less more? J Thorac Dis. 2016; 8(10): E1351–E1354.
  16. Chen L, Fan L, Luo Y, et al. Ex vivo mono-ring technique simplifies culotte stenting for treatment of true bifurcation lesions: Insights from bench testing and clinical application. Cardiol J. 2016; 23(6): 673–684.
  17. Kern A, Gil RJ, Bojko K, et al. The approach to coronary bifurcation treatment and its outcomes in Poland: The single center experience. Cardiol J. 2017; 24(6): 589–596.
  18. Bennett J, Adriaenssens T, Desmet W, et al. Complex bifurcation lesions: Randomized comparison of a fully bioresorbable modified t stenting strategy versus bifurcation reconstruction with a dedicated self-expanding stent in combination with bioresorbable scaffolds, an OCT study: Rationale and design of the COBRA II trial. Catheter Cardiovasc Interv. 2016; 88(6): 843–853.
  19. Verheye S, Buysschaert I, Grube E. Impact of side branch stenting on five-year long-term clinical outcome with the bifurcation-dedicated Axxess Biolimus A9-eluting stent system. EuroIntervention. 2015; 11(8): 860–867.
  20. Grundeken MJ, Wykrzykowska JJ, Ishibashi Y, et al. First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial. Catheter Cardiovasc Interv. 2016; 87(7): E248–E260.
  21. Stone G, Teirstein P, Meredith I, et al. Final five-year results of the platinum randomized trial comparing platinum chromium promus element and cobalt chromium promus/xience v everolimus-eluting stents in workhorse lesions. J Am Coll Cardiol. 2015; 65(10): A1733.
  22. Behan MW, Holm NR, de Belder AJ, et al. Coronary bifurcation lesions treated with simple or complex stenting: 5-year survival from patient-level pooled analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study. Eur Heart J. 2016; 37(24): 1923–1928.
  23. Maeng M, Holm NR, Erglis A, et al. Nordic-Baltic Percutaneous Coronary Intervention Study Group. Long-term results after simple versus complex stenting of coronary artery bifurcation lesions: Nordic Bifurcation Study 5-year follow-up results. J Am Coll Cardiol. 2013; 62(1): 30–34.
  24. Kang SJ, Mintz GS, Kim WJ, et al. Changes in left main bifurcation geometry after a single-stent crossover technique: an intravascular ultrasound study using direct imaging of both the left anterior descending and the left circumflex coronary arteries before and after intervention. Circ Cardiovasc Interv. 2011; 4(4): 355–361.
  25. Murasato Y, Horiuchi M, Otsuji Y. Three-dimensional modeling of double-stent techniques at the left main coronary artery bifurcation using micro-focus X-ray computed tomography. Catheter Cardiovasc Interv. 2007; 70(2): 211–220.